D. Rahul Ballal's Insider Trades & SAST Disclosures
D. Rahul Ballal's most recent trade in Enliven Therapeutics Inc was a trade of 20,491 Stock Option (right to buy) done . Disclosure was reported to the exchange on Feb. 6, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern D. Rahul Ballal.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Enliven Therapeutics Inc | Rahul D. Ballal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2025 | 20,491 | 20,491 | - | - | Stock Option (right to buy) | |
| Agios Pharmaceuticals Inc | Rahul D. Ballal | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Nov 2024 | 10,000 | 27,947 | - | - | Stock option (right to buy) | |
| Agios Pharmaceuticals Inc | Rahul D. Ballal | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Nov 2024 | 10,000 | 17,947 | - | - | Stock option (right to buy) | |
| Agios Pharmaceuticals Inc | Rahul D. Ballal | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 25.99 per share. | 07 Nov 2024 | 10,000 | 17,992 (0%) | 0% | 26.0 | 259,900 | Common stock |
| Agios Pharmaceuticals Inc | Rahul D. Ballal | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 25.99 per share. | 07 Nov 2024 | 10,000 | 17,992 (0%) | 0% | 26.0 | 259,900 | Common stock |
| Agios Pharmaceuticals Inc | Rahul D. Ballal | Director | Sale of securities on an exchange or to another person at price $ 53.32 per share. | 07 Nov 2024 | 8,132 | 9,860 (0%) | 0% | 53.3 | 433,598 | Common stock |
| Agios Pharmaceuticals Inc | Rahul D. Ballal | Director | Sale of securities on an exchange or to another person at price $ 58.57 per share. | 07 Nov 2024 | 4,929 | 9,492 (0%) | 0% | 58.6 | 288,692 | Common stock |
| Agios Pharmaceuticals Inc | Rahul D. Ballal | Director | Sale of securities on an exchange or to another person at price $ 57.24 per share. | 07 Nov 2024 | 3,571 | 14,421 (0%) | 0% | 57.2 | 204,404 | Common stock |
| Agios Pharmaceuticals Inc | Rahul D. Ballal | Director | Sale of securities on an exchange or to another person at price $ 54.41 per share. | 07 Nov 2024 | 1,868 | 7,992 (0%) | 0% | 54.4 | 101,638 | Common stock |
| Agios Pharmaceuticals Inc | Rahul D. Ballal | Director | Sale of securities on an exchange or to another person at price $ 59.21 per share. | 07 Nov 2024 | 1,500 | 7,992 (0%) | 0% | 59.2 | 88,815 | Common stock |
| Enliven Therapeutics Inc | Rahul D. Ballal | Director | Sale of securities on an exchange or to another person at price $ 28.17 per share. | 08 Oct 2024 | 10,420 | 22,341 | - | 28.2 | 293,557 | Common Stock |
| Enliven Therapeutics Inc | Rahul D. Ballal | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.68 per share. | 08 Oct 2024 | 6,314 | 28,655 | - | 19.7 | 124,260 | Common Stock |
| Enliven Therapeutics Inc | Rahul D. Ballal | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Oct 2024 | 6,314 | 69,428 | - | - | Stock Option (right to buy) | |
| Enliven Therapeutics Inc | Rahul D. Ballal | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.52 per share. | 08 Oct 2024 | 4,106 | 32,761 | - | 5.5 | 22,665 | Common Stock |
| Enliven Therapeutics Inc | Rahul D. Ballal | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Oct 2024 | 4,106 | 12,322 | - | - | Stock Option (right to buy) | |
| Agios Pharmaceuticals Inc | Rahul D. Ballal | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Aug 2024 | 2,302 | 7,992 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | Rahul D. Ballal | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Aug 2024 | 2,302 | 2,302 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | Rahul D. Ballal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 11,774 | 11,774 | - | - | Stock options (right to buy) | |
| Agios Pharmaceuticals Inc | Rahul D. Ballal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 2,120 | 2,120 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | Rahul D. Ballal | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jun 2024 | 3,388 | 0 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | Rahul D. Ballal | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jun 2024 | 3,388 | 5,690 (0%) | 0% | 0 | Common stock | |
| Enliven Therapeutics Inc | Rahul D. Ballal | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Apr 2024 | 48,820 | 0 | - | - | Stock Option (right to buy) | |
| Enliven Therapeutics Inc | Rahul D. Ballal | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.60 per share. | 10 Apr 2024 | 48,820 | 71,161 | - | 12.6 | 615,132 | Common Stock |
| Enliven Therapeutics Inc | Rahul D. Ballal | Director | Sale of securities on an exchange or to another person at price $ 23.14 per share. | 10 Apr 2024 | 30,300 | 45,441 | - | 23.1 | 701,024 | Common Stock |
| Enliven Therapeutics Inc | Rahul D. Ballal | Director | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 10 Apr 2024 | 20,032 | 25,409 | - | 25.0 | 500,702 | Common Stock |
| Enliven Therapeutics Inc | Rahul D. Ballal | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.60 per share. | 10 Apr 2024 | 13,600 | 35,941 | - | 12.6 | 171,360 | Common Stock |
| Enliven Therapeutics Inc | Rahul D. Ballal | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Apr 2024 | 13,600 | 48,820 | - | - | Stock Option (right to buy) | |
| Enliven Therapeutics Inc | Rahul D. Ballal | Director | Sale of securities on an exchange or to another person at price $ 21.01 per share. | 10 Apr 2024 | 13,600 | 22,341 | - | 21.0 | 285,744 | Common Stock |
| Enliven Therapeutics Inc | Rahul D. Ballal | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Apr 2024 | 4,580 | 75,742 | - | - | Stock Option (right to buy) | |
| Enliven Therapeutics Inc | Rahul D. Ballal | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.68 per share. | 10 Apr 2024 | 4,580 | 75,741 | - | 19.7 | 90,134 | Common Stock |
| Enliven Therapeutics Inc | Rahul D. Ballal | Director | Sale of securities on an exchange or to another person at price $ 25.21 per share. | 10 Apr 2024 | 3,068 | 22,341 | - | 25.2 | 77,342 | Common Stock |
| Enliven Therapeutics Inc | Rahul D. Ballal | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.60 per share. | 04 Apr 2024 | 3,485 | 25,826 | - | 12.6 | 43,911 | Common Stock |
| Enliven Therapeutics Inc | Rahul D. Ballal | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Apr 2024 | 3,485 | 62,420 | - | - | Stock Option (right to buy) | |
| Enliven Therapeutics Inc | Rahul D. Ballal | Director | Sale of securities on an exchange or to another person at price $ 19.15 per share. | 04 Apr 2024 | 3,485 | 22,341 | - | 19.1 | 66,729 | Common Stock |
| Enliven Therapeutics Inc | Rahul D. Ballal | Director | Sale of securities on an exchange or to another person at price $ 19.08 per share. | 01 Apr 2024 | 3,237 | 22,341 | - | 19.1 | 61,758 | Common Stock |
| Enliven Therapeutics Inc | Rahul D. Ballal | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2024 | 3,143 | 16,428 | - | - | Stock Option (right to buy) | |
| Enliven Therapeutics Inc | Rahul D. Ballal | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.52 per share. | 01 Apr 2024 | 3,143 | 25,578 | - | 5.5 | 17,349 | Common Stock |
| Enliven Therapeutics Inc | Rahul D. Ballal | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2024 | 94 | 65,905 | - | - | Stock Option (right to buy) | |
| Enliven Therapeutics Inc | Rahul D. Ballal | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.60 per share. | 01 Apr 2024 | 94 | 22,435 | - | 12.6 | 1,184 | Common Stock |
| Enliven Therapeutics Inc | Rahul D. Ballal | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Mar 2024 | 13,278 | 19,571 | - | - | Stock Option (right to buy) | |
| Enliven Therapeutics Inc | Rahul D. Ballal | Director | Sale of securities on an exchange or to another person at price $ 19.16 per share. | 20 Mar 2024 | 13,278 | 22,341 | - | 19.2 | 254,462 | Common Stock |
| Enliven Therapeutics Inc | Rahul D. Ballal | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.52 per share. | 20 Mar 2024 | 13,278 | 35,619 | - | 5.5 | 73,295 | Common Stock |
| Enliven Therapeutics Inc | D. Rahul Ballal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 23,364 | 23,364 | - | - | Stock Option (right to buy) | |
| Agios Pharmaceuticals Inc | Rahul D. Ballal | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Aug 2023 | 2,302 | 2,302 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | Rahul D. Ballal | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Aug 2023 | 2,302 | 4,604 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | Rahul D. Ballal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 18,958 | 18,958 | - | - | Stock options (right to buy) | |
| Agios Pharmaceuticals Inc | Rahul D. Ballal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 3,388 | 3,388 | - | - | Restricted stock units | |
| Enliven Therapeutics Inc | Rahul D. Ballal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 27,567 | 27,567 | - | - | Stock Option (right to buy) | |
| Agios Pharmaceuticals Inc | Rahul D. Ballal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Aug 2022 | 37,947 | 37,947 | - | - | Stock option (right to buy) | |
| Agios Pharmaceuticals Inc | Rahul D. Ballal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Aug 2022 | 6,906 | 6,906 | - | - | Restricted stock units |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges